Get started
Hims & Hers Health, Inc.Hims & Hers Health, Inc.Hims & Hers Health, Inc.

Hims & Hers Health, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

HIMS trade ideas

Hims demand zoneHims approaches the weekly demand zone on an outsized selloff. I believe this is way overboard here, the company makes money, and GLP is only about 5% of their revenue, they made money long before this. This demand zone would be a huge long term value entry for the stock. A wick past the 50 EMA would likely at least tap into this zone, albeit briefly. -I have been buying since 16$, I would love a snag at 13.15$ -Short-term bearish, medium and long term bullish
NYSE:HIMSShort
by Apollo_21mil
Him pivot (bullish)Hims is finally in an unrealistic zone, I have started to sell CSP between 14-16$ here to enter a position. You will note a tap of the 50 week EMA which serves as bullish momentum support. I updated the fibs and we have a severely bottomed stochastic RSI. This should be around the pivot zone. Remember most of these setups are on weekly charts so this will not be perfect. Regardless after fundamental analysis I am comfortable with buying here as well. -I expect 18-20$ this month whether its a wick or not -This volatility is very beneficial for people who sell options -I do have 17$ calls alongside my sold cash-secured puts
NYSE:HIMSLong
by Apollo_21mil
$HIMS - On it's last supportNYSE:HIMS I posted on July 20 that HIMS was losing momentum significantly and could drop to the $15–$14 area. Guess where it is now? It's currently trading around $15—a 22% drop from when I posted. Right now, HIMS is sitting on its last support level. If this support fails and the trendline breaks, $12 is a possibility. I’ve never understood HIMS's popularity among investors. To me, it always seemed like it was on borrowed time, just one or two litigations away from completely crashing down. But hey, I'm just an uninformed trader who missed that 100% epic run because of those fears, so don't mind me. As always, I share what I think and what I do. I'm not suggesting anyone follow my trades. You do you.
NYSE:HIMS
by PaperBozz
$HIMS | Allocation | Market Exec |Technical Confluences: - Price action is near the 50% Fibo retracement area - Price action have bounced off the 200 MA (Red) and has a valid Resistance Trendline with an Interest Zone nearby - Stochastics is inn Oversold conditions in the Daily & Weekly timeframes - Elliot Wave 4 seems to be completing at the 50% Fibo line and aim for the 100% Fibo Extension line @ 29.51 Fundamental Confluences: - Telemedicine with US being a focus market is great as healthcare issues seems to be increasing; demographics start to shift right - The main health markets that they target are issues that many in the society prefer to remain anonymous about and telemedicine solves that for them - One negative would be the high expenses they are spending on A&P budgets, a drag but overtime, we can see the impact of what they have been pushing all these while ________________________________ Putting NYSE:HIMS as part of my medical/health category of my portfolio. Will start my first allocation now and look at adding more into it if price moves into 50% - 61% Fibo range (Interest Zone). Remember, DYOR. ________________________________ Boosts 🚀, Follows ✌️, Shares 🙌 & Comments ✍️ are much appreciated! If you have any ideas or charts, do share them in the 'Comments' section below and we can discuss our perspectives to improve or strengthen our strategies. If you want something analyzed, do drop me a DM. :D ________________________________ Disclaimer: The above suggestion is an personal opinion in general and does not constitute as investment advice. Any decisions taken based on the above suggestion is purely your own risks. DYOR.
NYSE:HIMSLong
by weekendanalyst
New position HIMSI have traded this stock in the past and have been waiting for a dip. My plan is to sell covered-calls on this stock. I bought my first LEAP call today at a nice discount and am prepped to average down to the red dashed line if this occurs. I updated weekly fib extensions. The daily stochastic RSI is bottoming, but the weekly is peaking. If we reach around 25 $ on a base this would be forming a huge cup and handle. Strategy: 2026 LEAP calls ~1k each 15$ strikes, plan to exercise these in two years time Hopefully by then they will be paid off with premium and the stock will be well above 15$ This is my cash flow strategy for most of my accounts now
NYSE:HIMSLong
by Apollo_21mil
6/21/24 - $hims - Prefer other names, reassess <$15 k?6/21/24 :: VROCKSTAR :: NYSE:HIMS Prefer other names, reassess <$15 k? I'm going to keep the comment short bc this one is a sort of obvious "stay on the sidelines" to me. - stock has had a great bump since announcing they're selling cheap alts to the weight loss juice. cool. - great gross margins, but when you look at the SG&A (there's no R&D in this biz - which i don't like) the SG&A basically drives 100% of the gross profit. which means, perhaps they get some sort of leverage in the future but it's not happened yet. - good portfolio that allows a lot of cross/ up selling. but again refer to the prior comment. - so the cash gen is all we can hang our hats on today (not growth, or some sort of growth multiple), and they dilute a lot (see stock comp) more than the organic cash gen. - my conclusion is it's a great brand with great traction and recently great news. hence the stock move. but to get this thing higher and sustainably, we need either other larger announcements (unlikely), a few more Q's of results (that will take time), or some sort of buyout (I don't typically use this argument to own something unless the stock is reaching super low lows and there's some form of identifiable R&D value - not the case here - brand sure - but again - no inflection yet). the $15/shr target to take a look again is still a place i'd unlikely own it, but willing to reassess here. i think stock is probably worth closer to $10 all else equal today, but i know that won't earn me any fans holding the stock (tho i don't care bc i write these notes mainly for myself but publish for benefit of others if they can contribute thoughts that augment the thesis and we can make more money together). so don't get too hard just yet for this one. V
NYSE:HIMSShort
by VROCKSTAR
Hims & Hers Health, Inc. (NYSE: HIMS)Price Movement: The stock has shown significant volatility, with prices ranging from lows around $3-4 to highs over $25. Recent Spike: There's a notable price spike in early 2024, where the stock jumped to around $25 before quickly falling back. Trading Levels: Several price levels are marked, including $19.63, $16.88, and $12.87, which may represent key support or resistance levels. Trading Strategy: The chart includes annotations suggesting a trading strategy: "Buy Dip" levels are marked at lower prices ($3.96, around $10.30) A "Last Buy Position" is noted around the $12 level A "Sell Position" is marked near the peak of the 2024 spike A "Point To buy Again" is indicated after the price drop from the peak Current Trend: After the 2024 spike, the price appears to be in a downtrend, hovering around the $18-19 range. Long-term View: Despite volatility, the overall trend from 2021 to 2024 appears to be upward, with higher lows and higher highs. Volume: The chart includes volume bars at the bottom, showing periods of increased trading activity. This chart suggests that HIMS stock has been volatile but generally trending upward, with opportunities for both buying dips and selling at peaks. The annotations indicate a strategy of buying at lower prices and selling during significant price increases.
NYSE:HIMSShort
by Trustscore
HIMS - June 24 Qullamaggie Breakout and Episodic PivotI believe the inclusion of the compounded GLP-1 drug as part of their product offerings will driving strong sales and membership numbers in the next few months. 1) Their compounded GLP-1 is significantly cheaper 2) Their platform makes it easier and more accessible to purchase 3) It is lifestyle related so monthly recurring purchases is encouraged 4) HIMS is essentially a DTC business where capturing market share is crucial at this stage. In 2021 it was reported that they spend 48% of their revenue on marketing. As long as they can secure recurring purchases with a solid Average Order Value (AOV), they can gradually reduce and optimise expenses for new acquisitions once they have captured a significant market share. Not to mention the cross sell potential and the lower advertising costs for existing customers This is part of a Qullamaggie Breakout and Episodic Pivot study I am currently conducting Source @moizali - x.com www.triplewhale.com
NYSE:HIMSLong
by Ronin_trader
2
HIMS - June 24 (Broken Characters WIP)This is based on a new strategy that I started working on based on monitoring the larger price landscape and then observe character changes in the price action at key points. First new high Initial spike was brought about by news that HIMS would be launching its own branded GLP-1 medicines. These are the revolutionary weight loss drugs like Ozempic. Second new high Strong price movement with long full candles, but volume has slightly decreased. Third new high Price movement is dulling with significantly smaller candles and low voume Placed a small short bet that I will scale up if things go my way. Risk reward is good at 2.47 SL is based on me adding the ATR value on top of my entry What I am conflicted about is that the larger market regime is bullish
NYSE:HIMSShort
by Ronin_trader
1
Shares of Hims & Hers Health ($HIMS) Stock Surge 30% Digital pharmacy startup Hims & Hers Health ( NYSE:HIMS ) is introducing compounded GLP-1 weight loss injections, which have been gaining popularity due to supply constraints in the market. The company, which offers a range of direct-to-consumer treatments for conditions like erectile dysfunction and hair loss, launched a weight loss program in December but did not include GLP-1 medications such as Ozempic and Wegovy. Customers can access the compounded GLP-1 medications via a prescription from a licensed healthcare provider on the Hims & Hers platform. Hims & Hers ( NYSE:HIMS ) CEO Andrew Dudum said that the company is "confident" that customers will be able to access a consistent supply of the compounded medications. The company's oral medication kits start at $79 a month, and its compounded GLP-1 injections will start at $199 a month. The company expects its weight loss program to bring in more than $100 million in revenue by the end of 2025. The GLP-1 market, dominated by pharmaceutical giant Novo Nordisk, has faced supply constraints in recent months as drugs like Ozempic and Wegovy continue to skyrocket in popularity. The FDA does not review the safety and efficacy of compounded products, which are custom-made alternatives to brand drugs designed to meet a specific patient's needs. In a January release, the FDA said patients should not use a compounded GLP-1 drug if an approved drug, such as Wegovy, is available. Hims & Hers ( NYSE:HIMS ) Health's stock price is doing well, thanks to its strong growth and demand for its core products. It has surged by over 30% this year and by more than 112% this year, giving it a market cap of $3.13 billion. Hims & Hers Health's ( NYSE:HIMS ) business released data this month showing that its total revenue soared by 46% in Q1 to over $278 million, and its subscribers roared by 41% to 1.7 million. This performance makes it one of the fastest-growing companies in the US. Hims & Hers ( NYSE:HIMS ) expects revenue growth between $292 million and $297 million in Q2 while the adjusted EBITDA will be between $30 and $30 million. The company focuses on some of the biggest industries globally, including sex, anxiety, weight loss, hair, and skin, each of which has a total addressable market worth billions of dollars. Analysts believe that NYSE:HIMS revenue will jump to over $1.2 billion this year followed by $1.5 billion in 2025, which could help justify its hefty valuation.
NYSE:HIMSLong
by DEXWireNews